EMAIL THIS PAGE TO A FRIEND

American journal of physiology. Heart and circulatory physiology

Angiopoietin-1 prevents severe bleeding complications induced by heparin-like drugs and fibroblast growth factor-2 in mice.


PMID 26276817

Abstract

Critically ill children can develop bleeding complications when treated with heparin-like drugs. These events are usually attributed to the anticoagulant activity of these drugs. However, previous studies showed that fibroblast growth factor-2 (FGF-2), a heparin-binding growth factor released in the circulation of these patients, could precipitate intestinal hemorrhages in mice treated with the heparin-like drug pentosan polysulfate (PPS). Yet very little is known about how FGF-2 induces bleeding complications in combination with heparin-like drugs. Here, we examined the mechanisms by which circulating FGF-2 induces intestinal hemorrhages in mice treated with PPS. We used a well-characterized mouse model of intestinal hemorrhages induced by FGF-2 plus PPS. Adult FVB/N mice were infected with adenovirus carrying Lac-Z or a secreted form of recombinant human FGF-2, and injected with PPS, at doses that do not induce bleeding complications per se. Mice treated with FGF-2 in combination with PPS developed an intestinal inflammatory reaction that increased the permeability and disrupted the integrity of submucosal intestinal vessels. These changes, together with the anticoagulant activity of PPS, induced lethal hemorrhages. Moreover, a genetically modified form of the endothelial ligand angiopoietin-1 (Ang-1*), which has powerful antipermeability and anti-inflammatory activity, prevented the lethal bleeding complications without correcting the anticoagulant status of these mice. These findings define new mechanisms through which FGF-2 and Ang-1* modulate the outcome of intestinal bleeding complications induced by PPS in mice and may have wider clinical implications for critically ill children treated with heparin-like drugs.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

AV49445
Anti-ALG1 antibody produced in rabbit, affinity isolated antibody
SAB2700832
Anti-ALG1 antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
HPA060392
Anti-ALG1 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB1411095
Anti-ALG1 antibody produced in rabbit, purified immunoglobulin, buffered aqueous solution
SAB1305743
ANTI-CD106 (CENTER) antibody produced in rabbit, purified immunoglobulin, buffered aqueous solution
SAB1411900
ANTI-MT1A antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
SAB1406579
Anti-VCAM1 antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
SRP4038 Fgf-2 from mouse, recombinant, expressed in E. coli, ≥95% (SDS-PAGE), ≥95% (HPLC)
SRP4039 Fgf-2 from rat, recombinant, expressed in E. coli, ≥97% (SDS-PAGE), ≥97% (HPLC)
SAB4700521 Monoclonal Anti-CD106 antibody produced in mouse, clone STA, purified immunoglobulin, buffered aqueous solution
SAB1305520
MONOCLONAL ANTI-CD106 antibody produced in mouse, clone 582CT25.6.4, crude ascites, buffered aqueous solution
V9263 Monoclonal Anti-Vascular Cell Adhesion Molecule 1 antibody produced in mouse, ~1 mg/mL, clone 1.4C3, purified immunoglobulin, buffered aqueous solution
SAB1402959
Monoclonal Anti-VCAM1 antibody produced in mouse, clone 1H6, purified immunoglobulin, buffered aqueous solution
SAB4100447
Monoclonal Anti-VCAM1 antibody produced in mouse, clone VCAM1-B382, culture supernatant